Details
Modular program-based one-time assessment of incident celiac disease events among new users of specific Angiotensin Receptor Blockers (ARBS) including olmesartan, candesartan, eprosartan, irbesartan, losartan, telmisartan, and valsartan and new users of hydrochlorothiazide, atenolol, and amlodipine.Two main categories of counts were generated: 1) incident counts with respect to each of the medications, and 2) incident Celiac Disease events for each exposure group per 1000 person-days at risk [January 2007 – December 2011]. Modular programs are adaptable standardized programs. Results were generated using Modular Program 3; click here for more information. Programs were executed in August 2012.
If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.
The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.